Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1818543 | 0.98 | DNM1 (0.44) | DNM1ALDH1A1CNR1CNR2TSHR | |
| SCHEMBL11010126 | 0.89 | DNM1 (0.47) | DNM1ALDH1A1CNR1CNR2TSHR | |
| SCHEMBL27534986 | 0.84 | — | — | |
| SCHEMBL6752694 | 0.84 | TSHR (0.40) | DNM1ALDH1A1CNR1CNR2TSHR | |
| SCHEMBL15384183 | 0.83 | DNM1 (0.42) | DNM1ALDH1A1CNR1CNR2TSHR | |
| SCHEMBL6273275 | 0.83 | DNM1 (0.42) | DNM1ALDH1A1CNR1CNR2TSHR | |
| SCHEMBL4510013 | 0.80 | DNM1 (0.36) | DNM1ALDH1A1CNR1CNR2TSHR | |
| SCHEMBL4510009 | 0.79 | DNM1 (0.35) | DNM1ALDH1A1CNR1CNR2TSHR | |
| SCHEMBL9235342 | 0.79 | DNM1 (0.35) | DNM1ALDH1A1CNR1CNR2TSHR | |
| SCHEMBL6730804 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988417-B2 | Process for the preparation of estetrol | CRYSTAL PHARMA, S.A.U. (ES) | 2018-06-05 | — | — | US | claimed |
| EP-3046928-B1 | PROCESS FOR THE PREPARATION OF ESTETROL | CRYSTAL PHARMA SAU (ES) | 2017-02-08 | — | — | EP | claimed |
| US-20160229885-A1 | PROCESS FOR THE PREPARATION OF ESTETROL | CRYSTAL PHARMA, S.A.U. (ES) | 2016-08-11 | — | — | US | claimed |
| EP-3046928-A1 | PROCESS FOR THE PREPARATION OF ESTETROL | Crystal Pharma, S.A.U. (ES) | 2016-07-27 | — | — | EP | claimed |
| WO-2015040051-A1 | PROCESS FOR THE PREPARATION OF ESTETROL | CRYSTAL PHARMA, S.A.U. (ES) | 2015-03-26 | — | — | WO | claimed |
| WO-2013034780-A2 | PROCESS FOR THE PREPARATION OF ESTETROL AND RELATED COMPOUNDS | CRYSTAL PHARMA, S.A.U. (ES) | 2013-03-14 | — | — | WO | claimed |
| US-9988417-B2 | Process for the preparation of estetrol | CRYSTAL PHARMA, S.A.U. (ES) | 2018-06-05 | — | — | US | disclosed |
| EP-3046928-B1 | PROCESS FOR THE PREPARATION OF ESTETROL | CRYSTAL PHARMA SAU (ES) | 2017-02-08 | — | — | EP | disclosed |
| US-20160229885-A1 | PROCESS FOR THE PREPARATION OF ESTETROL | CRYSTAL PHARMA, S.A.U. (ES) | 2016-08-11 | — | — | US | disclosed |
| EP-3046928-A1 | PROCESS FOR THE PREPARATION OF ESTETROL | Crystal Pharma, S.A.U. (ES) | 2016-07-27 | — | — | EP | disclosed |
| WO-2015040051-A1 | PROCESS FOR THE PREPARATION OF ESTETROL | CRYSTAL PHARMA, S.A.U. (ES) | 2015-03-26 | — | — | WO | disclosed |
| WO-2013034780-A2 | PROCESS FOR THE PREPARATION OF ESTETROL AND RELATED COMPOUNDS | CRYSTAL PHARMA, S.A.U. (ES) | 2013-03-14 | — | — | WO | disclosed |
| US-8017776-B2 | Methods for synthesis of acyloxyalkyl compounds | XENOPORT, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| CN-1116292-C | Process for preparing benzodihydropyranol deriv. | BASF AG (DE) | 2003-07-30 | — | — | CN | disclosed |
| WO-2001020331-A9 | SUBSTRATES AND SCREENING METHODS FOR TRANSPORT PROTEINS | XENOPORT INC (US) | 2002-10-03 | — | — | WO | disclosed |
| EP-1212619-A1 | SUBSTRATES AND SCREENING METHODS FOR TRANSPORT PROTEINS | Xenoport, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001020331-A1 | SUBSTRATES AND SCREENING METHODS FOR TRANSPORT PROTEINS | XENOPORT, INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| CN-1249306-A | Process for preparing benzodihydropyranol deriv. | BASF AG (DE) | 2000-04-05 | — | — | CN | disclosed |
| US-5659021-A | Chiral glycerol derivatives | THE BOARD OF GOVERNORS FOR HIGHER EDUCATION, STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS (US) | 1997-08-19 | — | — | US | disclosed |
| US-4931575-A | Chiral glycerol derivatives | THE BOARD OF GOVERNORS FOR HIGHER EDUCATION, STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS (US) | 1990-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229885-A1 | PROCESS FOR THE PREPARATION OF ESTETROL | SRD5A2, VKORC1L1, SRD5A1 | DNM1 3635/4885ALDH1A1 591/4885CNR1 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.